1
|
Miller D, Reuillon T, Molyneux L, Blackburn T, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hardcastle I, Harnor SJ, Heptinstall A, Lochhead P, Martin MP, Martin NC, Myers S, Newell DR, Noble RA, Phillips N, Rigoreau L, Thomas H, Tucker JA, Wang LZ, Waring MJ, Wong AC, Wedge SR, Noble MEM, Cano C. Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. J Med Chem 2022; 65:6513-6540. [PMID: 35468293 PMCID: PMC9109144 DOI: 10.1021/acs.jmedchem.1c01756] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Indexed: 11/29/2022]
Abstract
The nonclassical extracellular signal-related kinase 5 (ERK5) mitogen-activated protein kinase pathway has been implicated in increased cellular proliferation, migration, survival, and angiogenesis; hence, ERK5 inhibition may be an attractive approach for cancer treatment. However, the development of selective ERK5 inhibitors has been challenging. Previously, we described the development of a pyrrole carboxamide high-throughput screening hit into a selective, submicromolar inhibitor of ERK5 kinase activity. Improvement in the ERK5 potency was necessary for the identification of a tool ERK5 inhibitor for target validation studies. Herein, we describe the optimization of this series to identify nanomolar pyrrole carboxamide inhibitors of ERK5 incorporating a basic center, which suffered from poor oral bioavailability. Parallel optimization of potency and in vitro pharmacokinetic parameters led to the identification of a nonbasic pyrazole analogue with an optimal balance of ERK5 inhibition and oral exposure.
Collapse
Affiliation(s)
- Duncan
C. Miller
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Tristan Reuillon
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Lauren Molyneux
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Timothy Blackburn
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Simon J. Cook
- Signalling
Laboratory, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, U.K.
| | - Noel Edwards
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Jane A. Endicott
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Bernard T. Golding
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Roger J. Griffin
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Ian Hardcastle
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Suzannah J. Harnor
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Amy Heptinstall
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Pamela Lochhead
- Signalling
Laboratory, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, U.K.
| | - Mathew P. Martin
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Nick C. Martin
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Stephanie Myers
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - David R. Newell
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Richard A. Noble
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Nicole Phillips
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Laurent Rigoreau
- Cancer
Research UK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Campus, Babraham, Cambridgeshire CB22 3AT, U.K.
| | - Huw Thomas
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Julie A. Tucker
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Lan-Zhen Wang
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Michael J. Waring
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| | - Ai-Ching Wong
- Cancer
Research UK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, U.K.
| | - Stephen R. Wedge
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Martin E. M. Noble
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre for Cancer, Paul O’Gorman Building, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
| | - Celine Cano
- Cancer
Research UK Newcastle Drug Discovery Unit, Newcastle University Centre
for Cancer, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.
| |
Collapse
|
3
|
Fadda AA, Tawfik EH, Abdel-Motaal M, Selim YA. Synthesis of novel cyanine dyes as antitumor agents. Arch Pharm (Weinheim) 2020; 354:e2000186. [PMID: 33169870 DOI: 10.1002/ardp.202000186] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 09/23/2020] [Accepted: 10/23/2020] [Indexed: 01/21/2023]
Abstract
In this study, some novel cyanine dyes, 1, 3, and 5-15, were synthesized by a one-pot step reaction of pyridinium salts 2 and/or 4 with benzenaminium salt 1. N-{[1-Chloro-3,4-dihydronaphthalen-2-yl)methylene]benzenaminium} chloride 1 was obtained by the reaction of α-tetralone with Vilsmeier-Haack reagent, followed by a mixture of an equimolar ratio of anilin/ethanol (1:1). All new cyanine dyes were evaluated in vitro for their anticancer activity against two cell lines, that is, HepG2 (human hepatocellular liver carcinoma) and MCF-7 (breast cancer). The obtained results were compared with human lung fibroblasts (WI-38) and Vero cells (derived from the kidney of an African green monkey) as normal cells. In particular, some of these compounds, 6, 9, 13, and 14, were found to be the most potent derivatives against all the cancer cell lines, without effect on the normal cells. According to the structure-activity relationship, compound 13 (IC50 = 8.8 µg/ml) exhibited a higher activity against HepG2 cells, as it contains the azo group and two phenyl rings and due to the presence of the π-conjugated system attached to the two pyridine rings. Compound 6 (IC50 = 8 µg/ml) exhibited a higher activity against MCF-7 cells, as it contains two chlorine atoms and the π-conjugated system of the pyridine rings.
Collapse
Affiliation(s)
- Ahmed A Fadda
- Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt
| | - Eman H Tawfik
- Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt.,Department of Chemistry, Faculty of Science and Arts, Taibah University, Ulla, Kingdom of Saudi Arabia
| | - Marwa Abdel-Motaal
- Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt.,Department of Chemistry, Faculty of Science and Arts, Qassim University, Qassim, Saudi Arabia
| | - Yasser A Selim
- Department of Chemistry, Faculty of Specific Education, Zagazig University, Zagazig, Egypt
| |
Collapse
|